Recurrent Adult Soft Tissue Sarcoma Completed Phase 2 Trials for Selumetinib (DB11689)

IndicationStatusPhase
DBCOND0028931 (Recurrent Adult Soft Tissue Sarcoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01206140Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By SurgeryTreatment